Congenital prothrombin deficiency: An update

Seminars in Thrombosis and Hemostasis

Volumn 39, Issue 6, 2013, Pages 596-606

  Lancellotti, Stefano ^a   Basso, Maria ^a   De Cristofaro, Raimondo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

coagulation; congenital bleeding diseases; hemorrhagic disorders; prothrombin deficiency; thrombin

Indexed keywords

FRESH FROZEN PLASMA; PROTHROMBIN; PROTHROMBIN COMPLEX;

ARTICLE; CHROMOSOME 11; DYSPROTHROMBINEMIA; ENZYME ACTIVE SITE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HYPOPROTHROMBINEMIA; LABORATORY DIAGNOSIS; LABORATORY TEST; MOLECULAR BIOLOGY; NONSENSE MUTATION; PARTIAL THROMBOPLASTIN TIME; PHENOTYPE; PLASMA TRANSFUSION; POLYMERASE CHAIN REACTION; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTHROMBIN DEFICIENCY; STRUCTURE ACTIVITY RELATION; SUBSTITUTION THERAPY;

BLOOD COAGULATION DISORDERS, INHERITED; CATALYTIC DOMAIN; GENOTYPE; HUMANS; MODELS, MOLECULAR; MUTATION; PROTHROMBIN; THROMBIN;

EID: 84883237947     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0033-1348948     Document Type: Article

References (91)

1. Lancellotti S., De Cristofaro R. Congenital prothrombin deficiency. Semin Thromb Hemost: 2009; 35 4 367 381
2. Barnhart M. I. Cellular site for prothrombin synthesis. Am J Physiol: 1960; 199 360 366
3. Mosesson M. W. Fibrinogen and fibrin structure and functions. J Thromb Haemost: 2005; 3 8 1894 1904
4. Esmon C. T. Regulation of blood coagulation. Biochim Biophys Acta: 2000; 1477 1-2 349 360
5. De Cristofaro R., De Candia E., Landolfi R., Rutella S., Hall S. W. Structural and functional mapping of the thrombin domain involved in the binding to the platelet glycoprotein Ib. Biochemistry: 2001; 40 44 13268 13273
6. De Candia E., Hall S. W., Rutella S., Landolfi R., Andrews R. K., De Cristofaro R. Binding of thrombin to glycoprotein Ib accelerates the hydrolysis of Par-1 on intact platelets. J Biol Chem: 2001; 276 7 4692 4698
7. Segers K., Dahlbäck B., Bock P. E., Tans G., Rosing J., Nicolaes G. A. The role of thrombin exosites I and II in the activation of human coagulation factor V. J Biol Chem: 2007; 282 47 33915 33924
8. Myles T., Yun T. H., Leung L. L. Structural requirements for the activation of human factor VIII by thrombin. Blood: 2002; 100 8 2820 2826
9. Isetti G., Maurer M. C. Employing mutants to study thrombin residues responsible for factor XIII activation peptide recognition: a kinetic study. Biochemistry: 2007; 46 9 2444 2452
10. Bar-Shavit R., Kahn A. J., Mann K. G., Wilner G. D. Identification of a thrombin sequence with growth factor activity on macrophages. Proc Natl Acad Sci U S A: 1986; 83 4 976 980
11. Zetter B. R., Antoniades H. N. Stimulation of human vascular endothelial cell growth by a platelet-derived growth factor and thrombin. J Supramol Struct: 1979; 11 3 361 370
12. Seino Y., Ikeda U., Ikeda M., et al. Interleukin 6 gene transcripts are expressed in human atherosclerotic lesions. Cytokine: 1994; 6 1 87 91
13. Fenton J. W. II. Regulation of thrombin generation and functions. Semin Thromb Hemost: 1988; 14 3 234 240
14. Siller-Matula J. M., Schwameis M., Blann A., Mannhalter C., Jilma B. Thrombin as a multi-functional enzyme. Focus on in vitro and in vivo effects. Thromb Haemost: 2011; 106 6 1020 1033
15. Degen S. J., Davie E. W. Nucleotide sequence of the gene for human prothrombin. Biochemistry: 1987; 26 19 6165 6177
16. Royle N. J., Irwin D. M., Koschinsky M. L., MacGillivray R. T., Hamerton J. L. Human genes encoding prothrombin and ceruloplasmin map to 11p11-q12 and 3q21-24, respectively. Somat Cell Mol Genet: 1987; 13 3 285 292
17. Akhavan S., Mannucci P. M., Lak M., et al. Identification and three-dimensional structural analysis of nine novel mutations in patients with prothrombin deficiency. Thromb Haemost: 2000; 84 6 989 997
18. Peyvandi F., Duga S., Akhavan S., Mannucci P. M. Rare coagulation deficiencies. Haemophilia: 2002; 8 3 308 321
19. Mannucci P. M., Duga S., Peyvandi F. Recessively inherited coagulation disorders. Blood: 2004; 104 5 1243 1252
20. Acharya S. S., Coughlin A., Dimichele D. M. North American Rare Bleeding Disorder Study Group Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. J Thromb Haemost: 2004; 2 2 248 256
21. Girolami A., Scarano L., Saggiorato G., Girolami B., Bertomoro A., Marchiori A. Congenital deficiencies and abnormalities of prothrombin. Blood Coagul Fibrinolysis: 1998; 9 7 557 569
22. Peyvandi F., Cattaneo M., Inbal A., De Moerloose P., Spreafico M. Rare bleeding disorders. Haemophilia: 2008; 14 03 202 210
23. Sun W. Y., Witte D. P., Degen J. L., et al. Prothrombin deficiency results in embryonic and neonatal lethality in mice. Proc Natl Acad Sci U S A: 1998; 95 13 7597 7602
24. Xue J., Wu Q., Westfield L. A., et al. Incomplete embryonic lethality and fatal neonatal hemorrhage caused by prothrombin deficiency in mice. Proc Natl Acad Sci U S A: 1998; 95 13 7603 7607
25. Iwahana H., Yoshimoto K., Shigekiyo T., Shirakami A., Saito S., Itakura M. Molecular and genetic analysis of a compound heterozygote for dysprothrombinemia of prothrombin Tokushima and hypoprothrombinemia. Am J Hum Genet: 1992; 51 6 1386 1395
26. Wang W., Fu Q., Zhou R., et al. Prothrombin Shanghai: hypoprothrombinaemia caused by substitution of Gla29 by Gly. Haemophilia: 2004; 10 1 94 97
27. Lanchantin G. F., Hart D. W., Friedmann J. A., Saavedra N. V., Mehl J. W. Amino acid composition of human plasma prothrombin. J Biol Chem: 1968; 243 20 5479 5485
28. Shapiro S. S., McCord S. Prothrombin. Prog Hemost Thromb: 1978; 4 177 209
29. Vu T. K., Hung D. T., Wheaton V. I., Coughlin S. R. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell: 1991; 64 6 1057 1068
30. Vouret-Craviari V., Boquet P., Pouysségur J., Van Obberghen-Schilling E. Regulation of the actin cytoskeleton by thrombin in human endothelial cells: role of Rho proteins in endothelial barrier function. Mol Biol Cell: 1998; 9 9 2639 2653
31. Schrör K., Bretschneider E., Fischer K., et al. Thrombin receptors in vascular smooth muscle cells - function and regulation by vasodilatory prostaglandins. Thromb Haemost: 2010; 103 5 884 890
32. Chung S., Kim J. E., Park S., Han K. S., Kim H. K. Neutrophil and monocyte activation markers have prognostic impact in disseminated intravascular coagulation: in vitro effect of thrombin on monocyte CD163 shedding. Thromb Res: 2011; 127 5 450 456
33. Pou J., Rebollo A., Piera L., et al. Tissue factor pathway inhibitor 2 is induced by thrombin in human macrophages. Biochim Biophys Acta: 2011; 1813 6 1254 1260
34. Hurley A., Smith M., Karpova T., et al. Enhanced effector function of CD8+ T Cells from healthy controls and HIV-infected patients occurs through thrombin activation of protease-activated receptor 1. J Infect Dis: 2013; 207 4 638 650
35. Bai K. J., Chen B. C., Pai H. C., et al. Thrombin-induced CCN2 expression in human lung fibroblasts requires the c-Src/JAK2/STAT3 pathway. J Leukoc Biol: 2013; 93 1 101 112
36. Dugina T. N., Kiseleva E. V., Glusa E., Strukova S. M. Activation of mast cells induced by agonists of proteinase-activated receptors under normal conditions and during acute inflammation in rats. Eur J Pharmacol: 2003; 471 2 141 147
37. Lee H., Hamilton J. R. Physiology, pharmacology, and therapeutic potential of protease-activated receptors in vascular disease. Pharmacol Ther: 2012; 134 2 246 259
38. Coughlin S. R. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost: 2005; 3 8 1800 1814
39. Dihanich M., Kaser M., Reinhard E., Cunningham D., Monard D. Prothrombin mRNA is expressed by cells of the nervous system. Neuron: 1991; 6 4 575 581
40. Kim S. R., Chung E. S., Bok E., et al. Prothrombin kringle-2 induces death of mesencephalic dopaminergic neurons in vivo and in vitro via microglial activation. J Neurosci Res: 2010; 88 7 1537 1548
41. Peyvandi F., Di Michele D., Bolton-Maggs P. H., Lee C. A., Tripodi A., Srivastava A. Project on Consensus Definitions in Rare Bleeeding Disorders of the Factor VIII/Factor IX Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis Classification of rare bleeding disorders (RBDs) based on the association between coagulant factor activity and clinical bleeding severity. J Thromb Haemost: 2012; 10 9 1938 1943
42. Akhavan S., De Cristofaro R., Peyvandi F., Lavoretano S., Landolfi R., Mannucci P. M. Molecular and functional characterization of a natural homozygous Arg67His mutation in the prothrombin gene of a patient with a severe procoagulant defect contrasting with a mild hemorrhagic phenotype. Blood: 2002; 100 4 1347 1353
43. Miyata T., Aruga R., Umeyama H., Bezeaud A., Guillin M. C., Iwanaga S. Prothrombin Salakta: substitution of glutamic acid-466 by alanine reduces the fibrinogen clotting activity and the esterase activity. Biochemistry: 1992; 31 33 7457 7462
44. Morishita E., Saito M., Kumabashiri I., Asakura H., Matsuda T., Yamaguchi K. Prothrombin Himi: a compound heterozygote for two dysfunctional prothrombin molecules (Met-337->Thr and Arg-388->His). Blood: 1992; 80 9 2275 2280
45. Di Cera E., Dang Q. D., Ayala Y. M. Molecular mechanisms of thrombin function. Cell Mol Life Sci: 1997; 53 9 701 730
46. Mota L., Ghosh K., Shetty S. Second trimester antenatal diagnosis in rare coagulation factor deficiencies. J Pediatr Hematol Oncol: 2007; 29 3 137 139
47. Van Creveld S. Congenital idiopathic hypoprothrombinemia. Acta Paediatr Suppl: 1954; 43 100 245 255
48. Miyawaki Y., Suzuki A., Fujita J., et al. Thrombosis from a prothrombin mutation conveying antithrombin resistance. N Engl J Med: 2012; 366 25 2390 2396
49. De Cristofaro R., Akhavan S., Altomare C., Carotti A., Peyvandi F., Mannucci P. M. A natural prothrombin mutant reveals an unexpected influence of A-chain structure on the activity of human alpha-thrombin. J Biol Chem: 2004; 279 13 13035 13043
50. De Cristofaro R., Carotti A., Akhavan S., et al. The natural mutation by deletion of Lys9 in the thrombin A-chain affects the pKa value of catalytic residues, the overall enzyme's stability and conformational transitions linked to Na+ binding. FEBS J: 2006; 273 1 159 169
51. Liu C. C., Brustad E., Liu W., Schultz P. G. Crystal structure of a biosynthetic sulfo-hirudin complexed to thrombin. J Am Chem Soc: 2007; 129 35 10648 10649
52. Napolitano M., Mariani G., Lapecorella M. Hereditary combined deficiency of the vitamin K-dependent clotting factors. Orphanet J Rare Dis: 2010; 5 21
53. Oldenburg J., von Brederlow B., Fregin A., et al. Congenital deficiency of vitamin K dependent coagulation factors in two families presents as a genetic defect of the vitamin K-epoxide-reductase-complex. Thromb Haemost: 2000; 84 6 937 941
54. Soute B. A., Ulrich M. M., Watson A. D., Maddison J. E., Ebberink R. H., Vermeer C. Congenital deficiency of all vitamin K-dependent blood coagulation factors due to a defective vitamin K-dependent carboxylase in Devon Rex cats. Thromb Haemost: 1992; 68 5 521 525
55. McMillan C. W., Roberts H. R. Congenital combined deficiency of coagulation factors II, VII, IX and X. Report of a case. N Engl J Med: 1966; 274 23 1313 1315
56. Brenner B., Tavori S., Zivelin A., et al. Hereditary deficiency of all vitamin K-dependent procoagulants and anticoagulants. Br J Haematol: 1990; 75 4 537 542
57. Lechler E. Use of prothrombin complex concentrates for prophylaxis and treatment of bleeding episodes in patients with hereditary deficiency of prothrombin, factor VII, factor X, protein C protein S, or protein Z. Thromb Res: 1999; 95 4 01 S39 S50
58. Owen C. A. Jr, Henriksen R. A., McDuffie F. C., Mann K. G. Prothrombin Quick. A newly identified dysprothrombinemia. Mayo Clin Proc: 1978; 53 1 29 33
59. Gill F. M., Shapiro S. S., Schwartz E. Severe congenital hypoprothrombinemia. J Pediatr: 1978; 93 2 264 266
60. Ostermann H., Haertel S., Knaub S., Kalina U., Jung K., Pabinger I. Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers. Thromb Haemost: 2007; 98 4 790 797
61. Bjorkman S., Collins P. Measurement of factor VIII pharmacokinetics in routine clinical practice. J Thromb Haemost: 2013; 11 1 180 182
62. Pabinger I., Brenner B., Kalina U., Knaub S., Nagy A., Ostermann H. Beriplex P/N Anticoagulation Reversal Study Group Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost: 2008; 6 4 622 631
63. Bode W., Turk D., Karshikov A. The refined 1.9-A X-ray crystal structure of D-Phe-Pro-Arg chloromethylketone-inhibited human alpha-thrombin: structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships. Protein Sci: 1992; 1 4 426 471
64. Girolami A., Santarossa L., Scarparo P., Candeo N., Girolami B. True congenital prothrombin deficiency due to a 'new' mutation in the pre-propeptide (ARG-39 GLN). Acta Haematol: 2008; 120 2 82 86
65. Wong A. Y., Hewitt J., Clarke B. J., et al. Severe prothrombin deficiency caused by prothrombin-Edmonton (R-4Q) combined with a previously undetected deletion. J Thromb Haemost: 2006; 4 12 2623 2628
66. Strijks E., Poort S. R., Renier W. O., Gabreëls F. J., Bertina R. M. Hereditary prothrombin deficiency presenting as intracranial haematoma in infancy. Neuropediatrics: 1999; 30 6 320 324
67. Poort S. R., Michiels J. J., Reitsma P. H., Bertina R. M. Homozygosity for a novel missense mutation in the prothrombin gene causing a severe bleeding disorder. Thromb Haemost: 1994; 72 6 819 824
68. Sun W. Y., Ruiz-Saez A., Burkart M. C., Bosch N., Degen S. J. Prothrombin carora: hypoprothrombinaemia caused by substitution of Tyr-44 by Cys. Br J Haematol: 1999; 105 3 670 672
69. Kulkarni B., Kanakia S., Ghosh K., Shetty S. Prothrombin Mumbai causes severe prothrombin deficiency due to a novel Cys90Ser mutation. Ann Hematol: 2012; 91 10 1667 1668
70. Poort S. R., Landolfi R., Bertina R. M. Compound heterozygosity for two novel missense mutations in the prothrombin gene in a patient with a severe bleeding tendency. Thromb Haemost: 1997; 77 4 610 615
71. Board P. G., Shaw D. C. Determination of the amino acid substitution in human prothrombin type 3 (157 Glu leads to Lys) and the localization of a third thrombin cleavage site. Br J Haematol: 1983; 54 2 245 254
72. Miyata T., Zheng Y. Z., Kato A., Kato H. A point mutation (Arg271→Cys) of a homozygote for dysfunctional prothrombin, prothrombin Obihiro, which has a region of high sequence variability. Br J Haematol: 1995; 90 3 688 692
73. James H. L., Kim D. J., Zheng D. Q., Girolami A. Prothrombin Padua I: incomplete activation due to an amino acid substitution at a factor Xa cleavage site. Blood Coagul Fibrinolysis: 1994; 5 5 841 844
74. François D., Chevreaud C., Vignon D., de Mazancourt P. Prothrombin Suresnes: a case of homozygous F299V mutation responsible for hypodysprothrombinemia. Haematologica: 2006; 91 3 431 432
75. Lefkowitz J. B., Haver T., Clarke S., et al. The prothrombin Denver patient has two different prothrombin point mutations resulting in Glu-300→Lys and Glu-309→Lys substitutions. Br J Haematol: 2000; 108 1 182 187
76. Akhavan S., Rocha E., Zeinali S., Mannucci P. M. Gly319 → arg substitution in the dysfunctional prothrombin Segovia. Br J Haematol: 1999; 105 3 667 669
77. Sun W. Y., Burkart M. C., Holahan J. R., Degen S. J. Prothrombin San Antonio: a single amino acid substitution at a factor Xa activation site (Arg320 to His) results in dysprothrombinemia. Blood: 2000; 95 2 711 714
78. Tamary H., Surrey S., Augustine J., Shalmon L., Schwartz E., Rappaport E. F. Molecular analysis of a compound heterozygote for hypoprothrombinemia and dysprothrombinemia (-G 7248/7249 and ARG 340 TRP). Blood Coagul Fibrinolysis: 1997; 8 6 337 343
79. Jayandharan G., Viswabandya A., Baidya S., et al. Molecular genetics of hereditary prothrombin deficiency in Indian patients: identification of a novel Ala362 → Thr (Prothrombin Vellore 1) mutation. J Thromb Haemost: 2005; 3 7 1446 1453
80. Henriksen R. A., Owen W. G., Nesheim M. E., Mann K. G. Identification of a congenital dysthrombin, thrombin Quick. J Clin Invest: 1980; 66 5 934 940
81. O'Marcaigh A. S., Nichols W. L., Hassinger N. L., et al. Genetic analysis and functional characterization of prothrombins Corpus Christi (Arg382-Cys), Dhahran (Arg271-His), and hypoprothrombinemia. Blood: 1996; 88 7 2611 2618
82. Girolami A., Coccheri S., Palareti G., Poggi M., Burul A., Cappellato G. Prothrombin Molise: a "newo" congenital dysprothrombinemia, double heterozygosis with an abnormal prothrombin and "trueo" prothrombin deficiency. Blood: 1978; 52 1 115 125
83. Iwahana H., Yoshimoto K., Shigekiyo T., Shirakami A., Saito S., Itakura M. Detection of a single base substitution of the gene for prothrombin Tokushima. The application of PCR-SSCP for the genetic and molecular analysis of dysprothrombinemia. Int J Hematol: 1992; 55 1 93 100
84. Kling S. J., Jones K. A., Rodgers G. M. A second case of prothrombin Puerto Rico I in the United States. Am J Hematol: 2007; 82 7 661 662
85. Lefkowitz J. B., Weller A., Nuss R., Santiago-Borrero P. J., Brown D. L., Ortiz I. R. A common mutation, Arg457->Gln, links prothrombin deficiencies in the Puerto Rican population. J Thromb Haemost: 2003; 1 11 2381 2388
86. Stanchev H., Philips M., Villoutreix B. O., Aksglaede L., Lethagen S., Thorsen S. Prothrombin deficiency caused by compound heterozygosity for two novel mutations in the prothrombin gene associated with a bleeding tendency. Thromb Haemost: 2006; 95 1 195 198
87. Henriksen R. A., Dunham C. K., Miller L. D., et al. Prothrombin Greenville, Arg517->Gln, identified in an individual heterozygous for dysprothrombinemia. Blood: 1998; 91 6 2026 2031
88. Sekine O., Sugo T., Ebisawa K., et al. Substitution of Gly-548 to Ala in the substrate binding pocket of prothrombin Perijá leads to the loss of thrombin proteolytic activity. Thromb Haemost: 2002; 87 2 282 287
89. Sun W. Y., Smirnow D., Jenkins M. L., Degen S. J. Prothrombin Scranton: substitution of an amino acid residue involved in the binding of Na+ (LYS-556 to THR) leads to dysprothrombinemia. Thromb Haemost: 2001; 85 4 651 654
90. Henriksen R. A., Mann K. G. Substitution of valine for glycine-558 in the congenital dysthrombin thrombin Quick II alters primary substrate specificity. Biochemistry: 1989; 28 5 2078 2082
91. Poort S. R., Njo K. T., Vos H. L., Bertina R. M. Two novel mutations in the prothrombin gene cause severe bleeding in a compound heterozygous patient. Blood Coagul Fibrinolysis: 1998; 9 8 761 764